Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
Kidney Medicine
|
May 30, 2023
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies
Fouad T Chebib, Xiaolei Zhou, Diana Garbinsky, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 24, 2026
Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023)
Courtney Levy, Sarah Sauchelli, Jessica L Abel, et al.
BMC Nephrology
|
June 22, 2023
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
Michael Lioudis, Xiaolei Zhou, Eric Davenport, et al.
BMC Nephrology
|
October 18, 2022
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, et al.
Frontiers in Dementia
|
July 31, 2024
Care partner evaluation of the behaviors in the Cohen-Mansfield Agitation Inventory
Dorothee Oberdhan, Andrew Palsgrove, Christy Houle, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 8, 2023
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease
Dorothee Oberdhan, Jason C Cole, Mark J Atkinson, et al.
Journal of Child and Adolescent Psychopharmacology
|
April 10, 2026
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Timothy E Wilens, Dorothee Oberdhan, Na Jin, et al.
Kidney Medicine
|
January 15, 2025
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis
Fouad T Chebib, Neera Dahl, Xiaolei Zhou, et al.
Kidney International Reports
|
May 16, 2022
Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
Xiaolei Zhou, Eric Davenport, John Ouyang, et al.
Kidney International Reports
|
June 11, 2020
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
Ronald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
Kidney Medicine
|
May 30, 2023
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies
Fouad T Chebib, Xiaolei Zhou, Diana Garbinsky, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 24, 2026
Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023)
Courtney Levy, Sarah Sauchelli, Jessica L Abel, et al.
BMC Nephrology
|
June 22, 2023
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
Michael Lioudis, Xiaolei Zhou, Eric Davenport, et al.
BMC Nephrology
|
October 18, 2022
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, et al.
Frontiers in Dementia
|
July 31, 2024
Care partner evaluation of the behaviors in the Cohen-Mansfield Agitation Inventory
Dorothee Oberdhan, Andrew Palsgrove, Christy Houle, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 8, 2023
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease
Dorothee Oberdhan, Jason C Cole, Mark J Atkinson, et al.
Journal of Child and Adolescent Psychopharmacology
|
April 10, 2026
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Timothy E Wilens, Dorothee Oberdhan, Na Jin, et al.
Kidney Medicine
|
January 15, 2025
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis
Fouad T Chebib, Neera Dahl, Xiaolei Zhou, et al.
Kidney International Reports
|
May 16, 2022
Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
Xiaolei Zhou, Eric Davenport, John Ouyang, et al.
Kidney International Reports
|
June 11, 2020
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
Ronald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.
Page
of 4